Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co And Incyte Corp's Arthritis Drug Shows Durability In Study-Reuters


Tuesday, 13 Nov 2012 05:00pm EST 

Reuters reported that a pill for rheumatoid arthritis being developed by Eli Lilly And Co and Incyte Corp maintained its effectiveness in reducing painful symptoms through 24 weeks of treatment in a midstage extension study, according to data presented at a medical meeting on Tuesday. A sub-study of patients taking part in the trial of the drug, baricitinib, also showed that the two highest doses tested helped to reduce joint damage, based on Magnetic Resonance Imaging (MRI) tests. The companies in June released positive data from the 301-subject Phase II study after 12 weeks of treatment in patients with mild to moderate RA who had an inadequate response to methotrexate. Four Phase III RA studies of baricitinib using the 2 milligram and 4 mg doses are planned for patients who have not previously been treated with methotrexate or injectable biotech drugs and also in patients who did have prior treatment with biologics, or drugs made from living organisms or their products, the companies said. Those studies will form the basis of the data package used to seek approval of the drug. After 24 weeks, 73% of patients who received 8 mg of the Lilly drug once daily achieved the ACR20 goal, or a 20% improvement in rheumatoid arthritis symptoms. That compared with 78% who hit ACR20 at 12 weeks. For the 4 mg dose, 78% of patients hit ACR 20 at 24 weeks, up from 75% at week 12. The study also measured ACR50 and ACR70 rates, or 50% and 70% improvement. 

Company Quote

62.77
-0.62 -0.98%
29 Jul 2014